In a filing, Veracyte Inc revealed its Chief Commercial Officer-CLIA Leite John unloaded Company’s shares for reported $76410.0 on Jun 04 ’25. In the deal valued at $27.20 per share,2,809 shares were sold. As a result of this transaction, Leite John now holds 94,540 shares worth roughly $2.63 million.
Then, JOHN LEITE bought 2,809 shares, generating $74,438 in total proceeds.
Before that, Leite John sold 7,411 shares. Veracyte Inc shares valued at $234,630 were divested by the Chief Commercial Officer-CLIA at a price of $31.66 per share. As a result of the transaction, Leite John now holds 100,249 shares, worth roughly $2.79 million.
Craig Hallum initiated its Veracyte Inc [VCYT] rating to a Buy in a research note published on March 20, 2025; the price target was $45. A number of analysts have revised their coverage, including Goldman’s analysts, who decreased its forecast for the stock in early December from “a Buy” to “a Neutral”. Wolfe Research began covering VCYT with “an Outperform” recommendation on November 15, 2024. UBS started covering the stock on October 16, 2024. It rated VCYT as “a Buy”.
Price Performance Review of VCYT
On Friday, Veracyte Inc [NASDAQ:VCYT] saw its stock jump 1.42% to $27.85. Over the last five days, the stock has gained 4.15%. Veracyte Inc shares have fallen nearly -29.67% since the year began. Nevertheless, the stocks have risen 27.69% over the past one year.
Levels Of Support And Resistance For VCYT Stock
The most recent change occurred on October 10, 2024 when Guggenheim began covering the stock and recommended ‘”a Buy”‘ rating along with a $40 price target.
